Market Outlook:

Squamous cell carcinoma of the head and neck (SCCHN) is an anatomically and biologically heterogeneous disease that has historically proven to be a complex challenge for drug development. In recent years, considerable advancements have been made, predominantly due to the emergence of immune checkpoint inhibitors. Merck & Co.’s Keytruda became the first immune checkpoint inhibitor to receive FDA approval in 2016, and it was the first new drug approved for SCCHN since Eli Lilly/Merck KGaA/Bristol-Myers Squibb’s Erbitux over ten years previously. Bristol-Myers Squibb’s PD-1 inhibitor Opdivo also received FDA approval in 2016, and EC and MHLW approvals followed in 2017, for previously treated metastatic or recurrent SCCHN. Clinical trials are now evaluating the role of immune checkpoint inhibitors in earlier stages of the disease, and several agents in this class are being positioned for the untapped and lucrative locoregionally advanced SCCHN setting, which is set to contribute to robust market growth throughout the 2017-2027 forecast period.

Questions Answered:

  • How large is the treatable SCCHN population, and how will diagnosis/drug-treatment rates change over time?
  • What is the current state of treatment in SCCHN?
  • Which are the most important drugs and why?
  • What are interviewed experts’ insights on current treatment options?
  • What clinical needs remain unfulfilled? What pipeline products are most promising, and what sales/uptake could they secure in SCCHN? What therapies of note are progressing in earlier phases?
  • The immune checkpoint inhibitor combinations (Keytruda plus chemotherapy, Opdivo plus Yervoy, and Imfinzi plus tremelimumab) are forecast for approval in which disease setting, and how will they compete with currently established therapies?
  • For which patient populations are immune checkpoint inhibitors most likely to be used?
  • What will be the impact on the SCCHN market?
  • What are the drivers and constraints in the SCCHN market, and how will the market evolve over the forecast period?

Product Description:

Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.


Related Reports

Squamous Cell Carcinoma of the Head and Neck | Current Treatment | Detailed, Expanded Analysis: Physician Insights (US)

Immune checkpoint inhibitors have transformed the treatment algorithm for recurrent or metastatic non-nasopharyngeal squamous cell carcinoma of the head and neck (

View Details

Squamous Cell Carcinoma of the Head and Neck | Current Treatment | Detailed, Expanded Analysis (US): Treatment Sequencing

KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.

View Details

Squamous Cell Carcinoma of the Head and Neck | Landscape & Forecast | Disease Landscape & Forecast

Market Outlook Treatment for recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN

View Details

Squamous Cell Carcinoma of the Head and Neck | Unmet Need | Detailed, Expanded Analysis: Recurrent or Metastatic Non-Nasopharyngeal SCCHN (US/EU)

Treatment of recurrent or metastatic non-nasopharyngeal squamous cell carcinoma of the head and neck (SCCHN) has remained relativ...

View Details